| NCT05707429 |
Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) |
NULL |
COMPLETED |
Assiut University |
Sexual Function Disturbances|Inflammatory Bowel D… |
OTHER: The Arabic version of The International In… |
Details |
| NCT05706038 |
Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse |
NULL |
COMPLETED |
IRCCS San Raffaele |
Inflammatory Bowel Diseases|Rheumatic Disorder |
DRUG: Adalimumab |
Details |
| NCT05687474 |
Baby Detect : Genomic Newborn Screening |
NULL |
COMPLETED |
Centre Hospitalier Universitaire de Liege |
Congenital Adrenal Hyperplasia|Familial Hyperinsu… |
None |
Details |
| NCT05668104 |
Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction |
NA |
COMPLETED |
Buddhist Tzu Chi General Hospital |
Healthy Subjects|COVID-19 Pneumonia|Irritable Bow… |
DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Pac… |
Details |
| NCT05643534 |
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
PHASE3 |
RECRUITING |
Ardelyx |
Irritable Bowel Syndrome With Constipation (IBS-C) |
DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… |
Details |
| NCT05626023 |
A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease |
PHASE1|PHASE2 |
COMPLETED |
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. |
Perianal Fistula|Crohn's Disease |
DRUG: Human TH-SC01 cell injection |
Details |
| NCT05588843 |
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Sanofi |
Colitis Ulcerative |
DRUG: SAR443122|DRUG: Placebo |
Details |
| NCT05584735 |
Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine |
NULL |
COMPLETED |
University of Wisconsin, Madison |
Inflammatory Bowel Diseases |
BIOLOGICAL: Influenza vaccine|BIOLOGICAL: COVID-1… |
Details |
| NCT05573685 |
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training |
NA |
COMPLETED |
Click Therapeutics, Inc. |
Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… |
DEVICE: DiNaMo Study App|DEVICE: Placebo App |
Details |
| NCT05542355 |
EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease |
PHASE1 |
TERMINATED |
Exeliom Biosciences |
Crohn Disease |
DRUG: EXL01|DRUG: Placebo|OTHER: SoC corticostero… |
Details |
| NCT05536440 |
A Study to Learn About Study Medicine Called PF-07261271 in Healthy People |
PHASE1 |
COMPLETED |
Pfizer |
Healthy |
DRUG: PF-07261271|DRUG: Placebo |
Details |
| NCT05528510 |
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis |
PHASE3 |
ACTIVE_NOT_RECRUITING |
Janssen Research & Development, LLC |
Colitis, Ulcerative |
DRUG: Guselkumab Dose 1|DRUG: Guselkumab Dose 2|D… |
Details |
| NCT07161297 |
Remimazolam for Colonoscopy in IBD Patients |
PHASE4 |
NOT_YET_RECRUITING |
Humanitas Clinical and Research Center |
IBD (Inflammatory Bowel Disease) |
DRUG: Intravenous remimazolam (5 mg initially, wi… |
Details |
| NCT05507931 |
Broccoli Sprouts for Mild Ulcerative Colitis |
NA |
COMPLETED |
University of Michigan |
Ulcerative Colitis|Ulcerative Colitis Chronic Mild |
DIETARY_SUPPLEMENT: 1 Serving of broccoli sprouts… |
Details |
| NCT05507203 |
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
PHASE3 |
COMPLETED |
Abivax S.A. |
Ulcerative Colitis |
DRUG: ABX464|DRUG: Placebo |
Details |
| NCT07156929 |
Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation |
NA |
COMPLETED |
University Hospital Schleswig-Holstein |
Respiratory Infection (for Example, Pneumonia, Br… |
DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… |
Details |
| NCT05466890 |
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) |
PHASE2 |
ACTIVE_NOT_RECRUITING |
Palatin Technologies, Inc |
Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… |
DRUG: PL8177 Placebo|DRUG: PL8177 |
Details |
| NCT05389709 |
A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting |
NULL |
COMPLETED |
Bayer |
Functional Gastrointestinal Disorders Such as Irr… |
DRUG: Iberogast (STW5-II, BAY98-7410) |
Details |
| NCT05377580 |
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis |
PHASE2 |
COMPLETED |
Innovent Biologics (Suzhou) Co. Ltd. |
Ulcerative Colitis (UC) |
DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… |
Details |
| NCT05372939 |
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET) |
PHASE2 |
COMPLETED |
Applied Molecular Transport |
Ulcerative Colitis |
DRUG: AMT-101 (oral)|OTHER: Placebo (oral)|COMBIN… |
Details |
